Table of Content

1 Leukotriene Inhibitors Market Overview
1.1 Product Overview and Scope of Leukotriene Inhibitors
1.2 Leukotriene Inhibitors Segment by Type
1.2.1 Global Leukotriene Inhibitors Market Value Comparison by Type (2024-2034)
1.2.2 Montelukast
1.2.3 Zafirlukast
1.2.4 Proust
1.2.5 Other
1.3 Leukotriene Inhibitors Segment by Application
1.3.1 Global Leukotriene Inhibitors Market Value by Application: (2024-2034)
1.3.2 Asthma
1.3.3 COPD
1.3.4 Allergic Rhinitis
1.3.5 Other
1.4 Global Leukotriene Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Leukotriene Inhibitors Revenue 2018-2029
1.4.2 Global Leukotriene Inhibitors Sales 2018-2029
1.4.3 Global Leukotriene Inhibitors Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Leukotriene Inhibitors Market Competition by Manufacturers
2.1 Global Leukotriene Inhibitors Sales Market Share by Manufacturers (2018-2024)
2.2 Global Leukotriene Inhibitors Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Leukotriene Inhibitors Average Price by Manufacturers (2018-2024)
2.4 Global Leukotriene Inhibitors Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Leukotriene Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Leukotriene Inhibitors, Product Type & Application
2.7 Leukotriene Inhibitors Market Competitive Situation and Trends
2.7.1 Leukotriene Inhibitors Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Leukotriene Inhibitors Players Market Share by Revenue
2.7.3 Global Leukotriene Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Leukotriene Inhibitors Retrospective Market Scenario by Region
3.1 Global Leukotriene Inhibitors Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Leukotriene Inhibitors Global Leukotriene Inhibitors Sales by Region: 2018-2029
3.2.1 Global Leukotriene Inhibitors Sales by Region: 2018-2024
3.2.2 Global Leukotriene Inhibitors Sales by Region: 2024-2029
3.3 Global Leukotriene Inhibitors Global Leukotriene Inhibitors Revenue by Region: 2018-2029
3.3.1 Global Leukotriene Inhibitors Revenue by Region: 2018-2024
3.3.2 Global Leukotriene Inhibitors Revenue by Region: 2024-2029
3.4 North America Leukotriene Inhibitors Market Facts & Figures by Country
3.4.1 North America Leukotriene Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Leukotriene Inhibitors Sales by Country (2018-2029)
3.4.3 North America Leukotriene Inhibitors Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Leukotriene Inhibitors Market Facts & Figures by Country
3.5.1 Europe Leukotriene Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Leukotriene Inhibitors Sales by Country (2018-2029)
3.5.3 Europe Leukotriene Inhibitors Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Leukotriene Inhibitors Market Facts & Figures by Country
3.6.1 Asia Pacific Leukotriene Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Leukotriene Inhibitors Sales by Country (2018-2029)
3.6.3 Asia Pacific Leukotriene Inhibitors Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Leukotriene Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Leukotriene Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Leukotriene Inhibitors Sales by Country (2018-2029)
3.7.3 Latin America Leukotriene Inhibitors Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Leukotriene Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Leukotriene Inhibitors Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Leukotriene Inhibitors Sales by Country (2018-2029)
3.8.3 Middle East and Africa Leukotriene Inhibitors Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Leukotriene Inhibitors Sales by Type (2018-2029)
4.1.1 Global Leukotriene Inhibitors Sales by Type (2018-2024)
4.1.2 Global Leukotriene Inhibitors Sales by Type (2024-2029)
4.1.3 Global Leukotriene Inhibitors Sales Market Share by Type (2018-2029)
4.2 Global Leukotriene Inhibitors Revenue by Type (2018-2029)
4.2.1 Global Leukotriene Inhibitors Revenue by Type (2018-2024)
4.2.2 Global Leukotriene Inhibitors Revenue by Type (2024-2029)
4.2.3 Global Leukotriene Inhibitors Revenue Market Share by Type (2018-2029)
4.3 Global Leukotriene Inhibitors Price by Type (2018-2029)
5 Segment by Application
5.1 Global Leukotriene Inhibitors Sales by Application (2018-2029)
5.1.1 Global Leukotriene Inhibitors Sales by Application (2018-2024)
5.1.2 Global Leukotriene Inhibitors Sales by Application (2024-2029)
5.1.3 Global Leukotriene Inhibitors Sales Market Share by Application (2018-2029)
5.2 Global Leukotriene Inhibitors Revenue by Application (2018-2029)
5.2.1 Global Leukotriene Inhibitors Revenue by Application (2018-2024)
5.2.2 Global Leukotriene Inhibitors Revenue by Application (2024-2029)
5.2.3 Global Leukotriene Inhibitors Revenue Market Share by Application (2018-2029)
5.3 Global Leukotriene Inhibitors Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Mallinckrodt plc
6.1.1 Mallinckrodt plc Corporation Information
6.1.2 Mallinckrodt plc Description and Business Overview
6.1.3 Mallinckrodt plc Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Mallinckrodt plc Leukotriene Inhibitors Product Portfolio
6.1.5 Mallinckrodt plc Recent Developments/Updates
6.2 Sun Pharmaceutical Industries Ltd
6.2.1 Sun Pharmaceutical Industries Ltd Corporation Information
6.2.2 Sun Pharmaceutical Industries Ltd Description and Business Overview
6.2.3 Sun Pharmaceutical Industries Ltd Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Sun Pharmaceutical Industries Ltd Leukotriene Inhibitors Product Portfolio
6.2.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
6.3 Novartis AG
6.3.1 Novartis AG Corporation Information
6.3.2 Novartis AG Description and Business Overview
6.3.3 Novartis AG Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Novartis AG Leukotriene Inhibitors Product Portfolio
6.3.5 Novartis AG Recent Developments/Updates
6.4 Endo Pharmaceuticals plc
6.4.1 Endo Pharmaceuticals plc Corporation Information
6.4.2 Endo Pharmaceuticals plc Description and Business Overview
6.4.3 Endo Pharmaceuticals plc Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Endo Pharmaceuticals plc Leukotriene Inhibitors Product Portfolio
6.4.5 Endo Pharmaceuticals plc Recent Developments/Updates
6.5 Zydus Cadila
6.5.1 Zydus Cadila Corporation Information
6.5.2 Zydus Cadila Description and Business Overview
6.5.3 Zydus Cadila Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Zydus Cadila Leukotriene Inhibitors Product Portfolio
6.5.5 Zydus Cadila Recent Developments/Updates
6.6 Mylan NV
6.6.1 Mylan NV Corporation Information
6.6.2 Mylan NV Description and Business Overview
6.6.3 Mylan NV Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.6.4 Mylan NV Leukotriene Inhibitors Product Portfolio
6.6.5 Mylan NV Recent Developments/Updates
6.7 Mayne Pharma Group Limited
6.6.1 Mayne Pharma Group Limited Corporation Information
6.6.2 Mayne Pharma Group Limited Description and Business Overview
6.6.3 Mayne Pharma Group Limited Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Mayne Pharma Group Limited Leukotriene Inhibitors Product Portfolio
6.7.5 Mayne Pharma Group Limited Recent Developments/Updates
6.8 Teva Pharmaceutical Industries Ltd
6.8.1 Teva Pharmaceutical Industries Ltd Corporation Information
6.8.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
6.8.3 Teva Pharmaceutical Industries Ltd Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Teva Pharmaceutical Industries Ltd Leukotriene Inhibitors Product Portfolio
6.8.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
6.9 Amneal Pharmaceutical Inc
6.9.1 Amneal Pharmaceutical Inc Corporation Information
6.9.2 Amneal Pharmaceutical Inc Description and Business Overview
6.9.3 Amneal Pharmaceutical Inc Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.9.4 Amneal Pharmaceutical Inc Leukotriene Inhibitors Product Portfolio
6.9.5 Amneal Pharmaceutical Inc Recent Developments/Updates
6.10 Avet Pharmaceuticals Inc
6.10.1 Avet Pharmaceuticals Inc Corporation Information
6.10.2 Avet Pharmaceuticals Inc Description and Business Overview
6.10.3 Avet Pharmaceuticals Inc Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Avet Pharmaceuticals Inc Leukotriene Inhibitors Product Portfolio
6.10.5 Avet Pharmaceuticals Inc Recent Developments/Updates
6.11 Aurobindo Pharma
6.11.1 Aurobindo Pharma Corporation Information
6.11.2 Aurobindo Pharma Leukotriene Inhibitors Description and Business Overview
6.11.3 Aurobindo Pharma Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.11.4 Aurobindo Pharma Leukotriene Inhibitors Product Portfolio
6.11.5 Aurobindo Pharma Recent Developments/Updates
6.12 GSK plc
6.12.1 GSK plc Corporation Information
6.12.2 GSK plc Leukotriene Inhibitors Description and Business Overview
6.12.3 GSK plc Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.12.4 GSK plc Leukotriene Inhibitors Product Portfolio
6.12.5 GSK plc Recent Developments/Updates
6.13 Almirall, SA
6.13.1 Almirall, SA Corporation Information
6.13.2 Almirall, SA Leukotriene Inhibitors Description and Business Overview
6.13.3 Almirall, SA Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.13.4 Almirall, SA Leukotriene Inhibitors Product Portfolio
6.13.5 Almirall, SA Recent Developments/Updates
6.14 Merck & Co., Inc
6.14.1 Merck & Co., Inc Corporation Information
6.14.2 Merck & Co., Inc Leukotriene Inhibitors Description and Business Overview
6.14.3 Merck & Co., Inc Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.14.4 Merck & Co., Inc Leukotriene Inhibitors Product Portfolio
6.14.5 Merck & Co., Inc Recent Developments/Updates
6.15 Bausch Health
6.15.1 Bausch Health Corporation Information
6.15.2 Bausch Health Leukotriene Inhibitors Description and Business Overview
6.15.3 Bausch Health Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.15.4 Bausch Health Leukotriene Inhibitors Product Portfolio
6.15.5 Bausch Health Recent Developments/Updates
6.16 Sandoz International GmbH
6.16.1 Sandoz International GmbH Corporation Information
6.16.2 Sandoz International GmbH Leukotriene Inhibitors Description and Business Overview
6.16.3 Sandoz International GmbH Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.16.4 Sandoz International GmbH Leukotriene Inhibitors Product Portfolio
6.16.5 Sandoz International GmbH Recent Developments/Updates
6.17 Circassia Pharmaceuticals
6.17.1 Circassia Pharmaceuticals Corporation Information
6.17.2 Circassia Pharmaceuticals Leukotriene Inhibitors Description and Business Overview
6.17.3 Circassia Pharmaceuticals Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.17.4 Circassia Pharmaceuticals Leukotriene Inhibitors Product Portfolio
6.17.5 Circassia Pharmaceuticals Recent Developments/Updates
6.18 AstraZeneca
6.18.1 AstraZeneca Corporation Information
6.18.2 AstraZeneca Leukotriene Inhibitors Description and Business Overview
6.18.3 AstraZeneca Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.18.4 AstraZeneca Leukotriene Inhibitors Product Portfolio
6.18.5 AstraZeneca Recent Developments/Updates
6.19 Sanofi
6.19.1 Sanofi Corporation Information
6.19.2 Sanofi Leukotriene Inhibitors Description and Business Overview
6.19.3 Sanofi Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.19.4 Sanofi Leukotriene Inhibitors Product Portfolio
6.19.5 Sanofi Recent Developments/Updates
6.20 McKesson Corporation
6.20.1 McKesson Corporation Corporation Information
6.20.2 McKesson Corporation Leukotriene Inhibitors Description and Business Overview
6.20.3 McKesson Corporation Leukotriene Inhibitors Sales, Revenue and Gross Margin (2018-2024)
6.20.4 McKesson Corporation Leukotriene Inhibitors Product Portfolio
6.20.5 McKesson Corporation Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Leukotriene Inhibitors Industry Chain Analysis
7.2 Leukotriene Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Leukotriene Inhibitors Production Mode & Process
7.4 Leukotriene Inhibitors Sales and Marketing
7.4.1 Leukotriene Inhibitors Sales Channels
7.4.2 Leukotriene Inhibitors Distributors
7.5 Leukotriene Inhibitors Customers
8 Leukotriene Inhibitors Market Dynamics
8.1 Leukotriene Inhibitors Industry Trends
8.2 Leukotriene Inhibitors Market Drivers
8.3 Leukotriene Inhibitors Market Challenges
8.4 Leukotriene Inhibitors Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Leukotriene Inhibitors Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Leukotriene Inhibitors Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Leukotriene Inhibitors Market Competitive Situation by Manufacturers in 2022
Table 4. Global Leukotriene Inhibitors Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Leukotriene Inhibitors Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Leukotriene Inhibitors Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Leukotriene Inhibitors Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Leukotriene Inhibitors Average Price (US$/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Leukotriene Inhibitors, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Leukotriene Inhibitors, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Leukotriene Inhibitors, Product Type & Application
Table 12. Global Key Manufacturers of Leukotriene Inhibitors, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Leukotriene Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Leukotriene Inhibitors as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Leukotriene Inhibitors Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Leukotriene Inhibitors Sales by Region (2018-2024) & (K Units)
Table 18. Global Leukotriene Inhibitors Sales Market Share by Region (2018-2024)
Table 19. Global Leukotriene Inhibitors Sales by Region (2024-2029) & (K Units)
Table 20. Global Leukotriene Inhibitors Sales Market Share by Region (2024-2029)
Table 21. Global Leukotriene Inhibitors Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Leukotriene Inhibitors Revenue Market Share by Region (2018-2024)
Table 23. Global Leukotriene Inhibitors Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Leukotriene Inhibitors Revenue Market Share by Region (2024-2029)
Table 25. North America Leukotriene Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Leukotriene Inhibitors Sales by Country (2018-2024) & (K Units)
Table 27. North America Leukotriene Inhibitors Sales by Country (2024-2029) & (K Units)
Table 28. North America Leukotriene Inhibitors Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Leukotriene Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Leukotriene Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Leukotriene Inhibitors Sales by Country (2018-2024) & (K Units)
Table 32. Europe Leukotriene Inhibitors Sales by Country (2024-2029) & (K Units)
Table 33. Europe Leukotriene Inhibitors Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Leukotriene Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Leukotriene Inhibitors Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Leukotriene Inhibitors Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Leukotriene Inhibitors Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Leukotriene Inhibitors Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Leukotriene Inhibitors Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Leukotriene Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Leukotriene Inhibitors Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Leukotriene Inhibitors Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Leukotriene Inhibitors Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Leukotriene Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Leukotriene Inhibitors Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Leukotriene Inhibitors Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Leukotriene Inhibitors Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Leukotriene Inhibitors Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Leukotriene Inhibitors Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Leukotriene Inhibitors Sales (K Units) by Type (2018-2024)
Table 51. Global Leukotriene Inhibitors Sales (K Units) by Type (2024-2029)
Table 52. Global Leukotriene Inhibitors Sales Market Share by Type (2018-2024)
Table 53. Global Leukotriene Inhibitors Sales Market Share by Type (2024-2029)
Table 54. Global Leukotriene Inhibitors Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Leukotriene Inhibitors Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Leukotriene Inhibitors Revenue Market Share by Type (2018-2024)
Table 57. Global Leukotriene Inhibitors Revenue Market Share by Type (2024-2029)
Table 58. Global Leukotriene Inhibitors Price (US$/Unit) by Type (2018-2024)
Table 59. Global Leukotriene Inhibitors Price (US$/Unit) by Type (2024-2029)
Table 60. Global Leukotriene Inhibitors Sales (K Units) by Application (2018-2024)
Table 61. Global Leukotriene Inhibitors Sales (K Units) by Application (2024-2029)
Table 62. Global Leukotriene Inhibitors Sales Market Share by Application (2018-2024)
Table 63. Global Leukotriene Inhibitors Sales Market Share by Application (2024-2029)
Table 64. Global Leukotriene Inhibitors Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Leukotriene Inhibitors Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Leukotriene Inhibitors Revenue Market Share by Application (2018-2024)
Table 67. Global Leukotriene Inhibitors Revenue Market Share by Application (2024-2029)
Table 68. Global Leukotriene Inhibitors Price (US$/Unit) by Application (2018-2024)
Table 69. Global Leukotriene Inhibitors Price (US$/Unit) by Application (2024-2029)
Table 70. Mallinckrodt plc Corporation Information
Table 71. Mallinckrodt plc Description and Business Overview
Table 72. Mallinckrodt plc Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 73. Mallinckrodt plc Leukotriene Inhibitors Product
Table 74. Mallinckrodt plc Recent Developments/Updates
Table 75. Sun Pharmaceutical Industries Ltd Corporation Information
Table 76. Sun Pharmaceutical Industries Ltd Description and Business Overview
Table 77. Sun Pharmaceutical Industries Ltd Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 78. Sun Pharmaceutical Industries Ltd Leukotriene Inhibitors Product
Table 79. Sun Pharmaceutical Industries Ltd Recent Developments/Updates
Table 80. Novartis AG Corporation Information
Table 81. Novartis AG Description and Business Overview
Table 82. Novartis AG Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 83. Novartis AG Leukotriene Inhibitors Product
Table 84. Novartis AG Recent Developments/Updates
Table 85. Endo Pharmaceuticals plc Corporation Information
Table 86. Endo Pharmaceuticals plc Description and Business Overview
Table 87. Endo Pharmaceuticals plc Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 88. Endo Pharmaceuticals plc Leukotriene Inhibitors Product
Table 89. Endo Pharmaceuticals plc Recent Developments/Updates
Table 90. Zydus Cadila Corporation Information
Table 91. Zydus Cadila Description and Business Overview
Table 92. Zydus Cadila Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 93. Zydus Cadila Leukotriene Inhibitors Product
Table 94. Zydus Cadila Recent Developments/Updates
Table 95. Mylan NV Corporation Information
Table 96. Mylan NV Description and Business Overview
Table 97. Mylan NV Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 98. Mylan NV Leukotriene Inhibitors Product
Table 99. Mylan NV Recent Developments/Updates
Table 100. Mayne Pharma Group Limited Corporation Information
Table 101. Mayne Pharma Group Limited Description and Business Overview
Table 102. Mayne Pharma Group Limited Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 103. Mayne Pharma Group Limited Leukotriene Inhibitors Product
Table 104. Mayne Pharma Group Limited Recent Developments/Updates
Table 105. Teva Pharmaceutical Industries Ltd Corporation Information
Table 106. Teva Pharmaceutical Industries Ltd Description and Business Overview
Table 107. Teva Pharmaceutical Industries Ltd Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 108. Teva Pharmaceutical Industries Ltd Leukotriene Inhibitors Product
Table 109. Teva Pharmaceutical Industries Ltd Recent Developments/Updates
Table 110. Amneal Pharmaceutical Inc Corporation Information
Table 111. Amneal Pharmaceutical Inc Description and Business Overview
Table 112. Amneal Pharmaceutical Inc Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 113. Amneal Pharmaceutical Inc Leukotriene Inhibitors Product
Table 114. Amneal Pharmaceutical Inc Recent Developments/Updates
Table 115. Avet Pharmaceuticals Inc Corporation Information
Table 116. Avet Pharmaceuticals Inc Description and Business Overview
Table 117. Avet Pharmaceuticals Inc Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 118. Avet Pharmaceuticals Inc Leukotriene Inhibitors Product
Table 119. Avet Pharmaceuticals Inc Recent Developments/Updates
Table 120. Aurobindo Pharma Corporation Information
Table 121. Aurobindo Pharma Description and Business Overview
Table 122. Aurobindo Pharma Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 123. Aurobindo Pharma Leukotriene Inhibitors Product
Table 124. Aurobindo Pharma Recent Developments/Updates
Table 125. GSK plc Corporation Information
Table 126. GSK plc Description and Business Overview
Table 127. GSK plc Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 128. GSK plc Leukotriene Inhibitors Product
Table 129. GSK plc Recent Developments/Updates
Table 130. Almirall, SA Corporation Information
Table 131. Almirall, SA Description and Business Overview
Table 132. Almirall, SA Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 133. Almirall, SA Leukotriene Inhibitors Product
Table 134. Almirall, SA Recent Developments/Updates
Table 135. Merck & Co., Inc Corporation Information
Table 136. Merck & Co., Inc Description and Business Overview
Table 137. Merck & Co., Inc Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 138. Merck & Co., Inc Leukotriene Inhibitors Product
Table 139. Merck & Co., Inc Recent Developments/Updates
Table 140. Bausch Health Corporation Information
Table 141. Bausch Health Description and Business Overview
Table 142. Bausch Health Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 143. Bausch Health Leukotriene Inhibitors Product
Table 144. Bausch Health Recent Developments/Updates
Table 145. Sandoz International GmbH Corporation Information
Table 146. Sandoz International GmbH Description and Business Overview
Table 147. Sandoz International GmbH Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 148. Sandoz International GmbH Leukotriene Inhibitors Product
Table 149. Sandoz International GmbH Recent Developments/Updates
Table 150. Circassia Pharmaceuticals Corporation Information
Table 151. Circassia Pharmaceuticals Description and Business Overview
Table 152. Circassia Pharmaceuticals Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 153. Circassia Pharmaceuticals Leukotriene Inhibitors Product
Table 154. Circassia Pharmaceuticals Recent Developments/Updates
Table 155. AstraZeneca Corporation Information
Table 156. AstraZeneca Description and Business Overview
Table 157. AstraZeneca Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 158. AstraZeneca Leukotriene Inhibitors Product
Table 159. AstraZeneca Recent Developments/Updates
Table 160. Sanofi Corporation Information
Table 161. Sanofi Description and Business Overview
Table 162. Sanofi Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 163. Sanofi Leukotriene Inhibitors Product
Table 164. Sanofi Recent Developments/Updates
Table 165. McKesson Corporation Corporation Information
Table 166. McKesson Corporation Description and Business Overview
Table 167. McKesson Corporation Leukotriene Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 168. McKesson Corporation Leukotriene Inhibitors Product
Table 169. McKesson Corporation Recent Developments/Updates
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Leukotriene Inhibitors Distributors List
Table 173. Leukotriene Inhibitors Customers List
Table 174. Leukotriene Inhibitors Market Trends
Table 175. Leukotriene Inhibitors Market Drivers
Table 176. Leukotriene Inhibitors Market Challenges
Table 177. Leukotriene Inhibitors Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Leukotriene Inhibitors
Figure 2. Global Leukotriene Inhibitors Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Leukotriene Inhibitors Market Share by Type in 2022 & 2029
Figure 4. Montelukast Product Picture
Figure 5. Zafirlukast Product Picture
Figure 6. Proust Product Picture
Figure 7. Other Product Picture
Figure 8. Global Leukotriene Inhibitors Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global Leukotriene Inhibitors Market Share by Application in 2022 & 2029
Figure 10. Asthma
Figure 11. COPD
Figure 12. Allergic Rhinitis
Figure 13. Other
Figure 14. Global Leukotriene Inhibitors Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Leukotriene Inhibitors Market Size (2018-2029) & (US$ Million)
Figure 16. Global Leukotriene Inhibitors Sales (2018-2029) & (K Units)
Figure 17. Global Leukotriene Inhibitors Average Price (US$/Unit) & (2018-2029)
Figure 18. Leukotriene Inhibitors Report Years Considered
Figure 19. Leukotriene Inhibitors Sales Share by Manufacturers in 2022
Figure 20. Global Leukotriene Inhibitors Revenue Share by Manufacturers in 2022
Figure 21. The Global 5 and 10 Largest Leukotriene Inhibitors Players: Market Share by Revenue in 2022
Figure 22. Leukotriene Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 23. Global Leukotriene Inhibitors Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 24. North America Leukotriene Inhibitors Sales Market Share by Country (2018-2029)
Figure 25. North America Leukotriene Inhibitors Revenue Market Share by Country (2018-2029)
Figure 26. United States Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Canada Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Europe Leukotriene Inhibitors Sales Market Share by Country (2018-2029)
Figure 29. Europe Leukotriene Inhibitors Revenue Market Share by Country (2018-2029)
Figure 30. Germany Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. France Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. U.K. Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Italy Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Russia Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Asia Pacific Leukotriene Inhibitors Sales Market Share by Region (2018-2029)
Figure 36. Asia Pacific Leukotriene Inhibitors Revenue Market Share by Region (2018-2029)
Figure 37. China Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Japan Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. South Korea Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. India Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Australia Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. China Taiwan Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Southeast Asia Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Leukotriene Inhibitors Sales Market Share by Country (2018-2029)
Figure 45. Latin America Leukotriene Inhibitors Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Leukotriene Inhibitors Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Leukotriene Inhibitors Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. UAE Leukotriene Inhibitors Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Leukotriene Inhibitors by Type (2018-2029)
Figure 55. Global Revenue Market Share of Leukotriene Inhibitors by Type (2018-2029)
Figure 56. Global Leukotriene Inhibitors Price (US$/Unit) by Type (2018-2029)
Figure 57. Global Sales Market Share of Leukotriene Inhibitors by Application (2018-2029)
Figure 58. Global Revenue Market Share of Leukotriene Inhibitors by Application (2018-2029)
Figure 59. Global Leukotriene Inhibitors Price (US$/Unit) by Application (2018-2029)
Figure 60. Leukotriene Inhibitors Value Chain
Figure 61. Leukotriene Inhibitors Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed